Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.
You may also be interested in...
Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.